Novartis Ag

Novartis Pharma Gmbh

Walter Schuler

Peter Von Matt

Maurice Van Eis

Jean-Pierre Evenou

Jürgen Wagner

Franco E Di Padova

Markus Warmuth

Gisbert Weckbecker

Theodor Fehr

Frank Peter Stegmeier

Lukas Oberer

Hans-Günter Zerwes

Hendrik Schuurman

Hans-G&uuml;nter Zerwes

Valerie Quesniaux Ryffel

Jean-Jacques Sanglier

Johannes Schuurmann Hessel

The present invention demonstrates that chronic active BCR signaling through CD79A/B confers a strong dependence on downstream PKCb kinase signaling. Hence, provided herein is a method for inhibiting the growth of B-cell lymphoma having chronic active B-cell-receptor signaling, or inhibiting the growth of cancers with molecular lesions that lead to chronic active BCR signaling, by administering to a patient in need of such treatment a therapeutically effective amount of a PKC inhibitor or a use of a PKC inhibitor to inhibit the growth of B-cell lymphoma having chronic active B-cell-receptor signaling or to inhibit the growth of cancers with molecular lesions that lead to chronic active BCR signaling.

Use of a PKC inhibitor

A compound of formula (I), wherein R, R, R, ring A, which ring contains one or two nitrogen atoms, and ring B are as defined in the Specification, pharmaceutical compositions containing these compounds, and uses for these compounds and compositions, in particular, in transplantation. 

Indolymaleimide derivatives

A compound of formula (I) wherein R, R, and R, ring A and ring B are as defined in the specification, processes for their production, their uses, in particular in transplantation, and pharmaceutical compositions containing them.

Indolylmaleimide derivatives

This invention relates to PKC inhibitors which are able to selectively inhibit e.g. the and optionally 0, isoforms of PKC, and their use in particular in transplantation.

Indolylmaleimide derivatives as PKC inhibitors

A CD154 binding molecule, in particular an antibody to human CD154, especially a human antibody to human CD154 is provided, wherein the CDRs of the heavy chain and light chain have amino acid sequences as defined, for use in the treatment and/or prevention of diseases or disorders wherein CD154 modulation and/or interference with or inhibition of the CD154:CD40 interactions is therapeutically beneficial.

Human CD154 binding molecules and treatment methods

This invention relates to the use of 40-O-(2-hydroxy)ethyl-rapamycin for the prevention or treatment of neointimal proliferation and thickening, restenosis, and vascular occlusion following vascular injury.

Use of 40-O-(2-hydroxy)ethylrapamycin for treatment of restenosis and other disorders

Macrolides

Growing community of inventors

Grenzach-Wyhlen, Germany

Walter Schuler